Skip to content
ATLAS PREP HQ
Longevity

Cortagen

Ala-Glu-Asp-Pro (AEDP) tetrapeptide bioregulator

Peptide bioregulator research focused on neuroregeneration, brain aging, and cognitive function.

Preclinical Evidence

Route

Subcutaneous in the community educational protocol.

Common format

20 mg vial

Research focus

nerve regeneration

Evidence level

Preclinical Evidence

Typical cycle

4 weeks

Longevity research motifLongevity

Cortagen in 30 seconds

Atlas Fast Read

What it is

Ala-Glu-Asp-Pro (AEDP) tetrapeptide bioregulator

Why people care

Peptide bioregulator research focused on neuroregeneration, brain aging, and cognitive function.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

Cortagen is scientifically interesting for nerve regeneration, cerebral ischemia, but the current case is driven mainly by cell and animal data.

Overview

What is Cortagen?

Cortagen is ala-Glu-Asp-Pro (AEDP) tetrapeptide bioregulator. Peptide bioregulator research focused on neuroregeneration, brain aging, and cognitive function.

Developed in the Khavinson peptide-bioregulator program from cortex-derived peptide research. Published work has focused on neuroprotection, gene regulation, and peripheral-nerve regeneration, largely in preclinical models.

Mechanism

How it works

Short-peptide bioregulator proposed to influence gene expression and neurotrophic/stress-response proteins. Animal work suggests reduced oxidative injury and improved neurite/nerve regeneration.

Research areas

nerve regenerationcerebral ischemiacognitionoxidative stress

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Published human evidence is sparse and not sufficient to establish Cortagen as an effective neuroregenerative or cognitive treatment. Most claims remain grounded in Russian peptide-bioregulator work and animal/cell models.

Preclinical evidence

Animal and cell models report neuroprotective effects, reduced oxidative damage, altered gene expression, and improved peripheral-nerve regeneration. These findings have not been established in large human trials.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community research reference: 1 mg/day for 2 weeks then 2 mg/day for 2 weeks.

Frequency

Once daily.

Timing

Community sources suggest morning; not clinically validated.

Route

Subcutaneous in the community educational protocol.

Cycle length

4 weeks

Reconstitution

Community reference: 2 mL bacteriostatic water per 20 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C, protect from light, avoid freeze-thaw.

Monitoring

No validated monitoring protocol. Track cognitive/neurologic outcomes and adverse effects; CBC/CMP are general safety tests rather than Cortagen-specific markers.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Systematic human safety data are limited. Reported or plausible effects include headache, dizziness, fatigue, irritability, sleep changes, nausea and injection/nasal-site irritation depending on route.

Contraindications

No validated broad contraindication profile exists. Avoid unsupervised use in pregnancy/breastfeeding, severe psychiatric instability, seizure disorders or major neurologic disease unless the research/clinical protocol specifically addresses it.

Interactions

Formal interaction studies are limited. CNS-active medicines, sedatives, stimulants, antidepressants, anxiolytics and anticonvulsants may alter or obscure effects and should be reviewed clinically.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Cortagen is scientifically interesting for nerve regeneration, cerebral ischemia, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Longevity

Longevity

Epitalon

Pineal-derived tetrapeptide research exploring telomerase activity, circadian biology, and healthy aging.

Read guide

Longevity

FOXO4-DRI

Experimental senolytic peptide research investigating selective removal of senescent cells.

Read guide

Longevity

Glutathione

Antioxidant research focused on redox balance, oxidative stress, and cellular detoxification pathways.

Read guide